AB Science SA
Uždarymo kaina
0.95 1.71
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
0.908
Max
0.95
Pajamos | 8.8M 3.6M |
|---|---|
Pardavimai | 144K 659K |
Pelno marža | 549.317 |
Darbuotojai | 36 |
EBITDA | 1.8M -727K |
Rinkos kapitalizacija | -628K 68M |
|---|---|
Ankstesnė atidarymo kaina | -0.76 |
Ankstesnė uždarymo kaina | 0.95 |
AB Science SA Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Susijusios naujienos
Akcijų palyginimas
Kainos pokytis
AB Science SA Prognozė
Finansinės naujienos
Pardavimo ir administravimo išlaidos
Veiklos sąnaudos
Ikimokestinis pelnas
Pardavimai
Pardavimo savikaina
Bendrasis pelnas iš pardavimo
Skolų palūkanų išlaidos
EBITDA
Veiklos pelnas
$
Apie bendrovę AB Science SA
AB Science S.A., a clinical-stage company, designs and develops novel drugs to various diseases with high unmet medical needs for inflammatory diseases, pathologies affecting peripheral and central nervous system, and cancers in France. The company's lead compound is the masitinib, a tyrosine kinase inhibitor which is in Phase III clinical trials for the treatment of amyotrophic lateral sclerosis, indolent systemic mastocytosis, severe asthma, progressive forms of multiple sclerosis, first line pancreatic cancer with pain, alzheimer's disease, and metastatic castrate-resistant prostate cancer, as well as in Phase II clinical trial to treat Covid-19. It also developing AB8939, a microtubule destabiliser for acute myeloid leukemia. The company markets its masitinib under the Masivet brand in Europe. AB Science S.A. was incorporated in 2001 and is headquartered in Paris, France.
